Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | FPR2 | P25090 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2881471 | 0.85 | NPC1 (0.53) | MAPTTP53LMNANPC1RAB9A | |
| SCHEMBL2569997 | 0.83 | MAPT (0.48) | MAPTTP53LMNANPC1RAB9A | |
| SCHEMBL1595003 | 0.78 | EPHX2 (0.55) | MAPTNPC1RAB9AFPR2KMT2A | |
| SCHEMBL2568635 | 0.78 | NAMPT (0.55) | LMNARAB9ASMN1; SMN2 | |
| SCHEMBL4118553 | 0.77 | NPC1 (0.69) | MAPTTP53LMNANPC1RAB9A | |
| SCHEMBL2562045 | 0.77 | NPC1 (0.49) | MAPTTP53LMNANPC1RAB9A | |
| SCHEMBL1594485 | 0.76 | EPHX2 (0.59) | NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL1594762 | 0.75 | MAPT (0.46) | MAPTLMNANPC1RAB9AALDH1A1 | |
| SCHEMBL2569818 | 0.75 | MEN1 (0.40) | MAPTTP53LMNANPC1RAB9A | |
| SCHEMBL4112024 | 0.74 | NPC1 (0.63) | MAPTLMNANPC1RAB9AFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732901-B1 | ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND | AICURIS GMBH & CO KG (DE) | 2011-11-02 | — | — | EP | disclosed |
| EP-1732901-B1 | ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND | AICURIS GMBH & CO KG (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-7767704-B2 | Antiviral 4-aminocarbonylamino-substituted imidazole compounds | AICURIS GMBH & CO. KG (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7767704-B2 | Antiviral 4-aminocarbonylamino-substituted imidazole compounds | AICURIS GMBH & CO. KG (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7767704-B2 | Antiviral 4-aminocarbonylamino-substituted imidazole compounds | AICURIS GMBH & CO. KG (DE) | 2010-08-03 | — | — | US | disclosed |
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | BAYER HEALTHCARE AG (DE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | BAYER HEALTHCARE AG (DE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | BAYER HEALTHCARE AG (DE) | 2008-01-03 | — | — | US | disclosed |
| EP-1732901-A1 | ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND | Bayer HealthCare AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005092865-A1 | ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND | BAYER HEALTHCARE AG (DE) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | IRF3, EIF2AK2, ZC3HAV1 | MAPT 3312/4885TP53 935/4885LMNA 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.